Pharmacokinetics of Pegylated Liposomal Doxorubicin: Review of Animal and Human Studies

By Gabizon A.   Shmeeda H.  

Clinical Pharmacokinetics, Vol. 42, Iss. 5, 2003-01 ,pp. : 419-436

Adis International

Access to resources Recommend Favorite

Bioavailability and therapeutic efficacy of HER2 scFv-targeted liposomal doxorubicin in a murine model of HER2-overexpressing breast cancer

By Laginha Kimberley   Moase Elaine   Yu Ning   Huang Anthony   Allen T. M.  

Journal of Drug Targeting, Vol. 16, Iss. 7-8, 2008-08 ,pp. : 605-610

Informa Healthcare

Access to resources Recommend Favorite

Phase I study of liposomal doxorubicin (Doxil) and cyclophosphamide in solid tumors

By El-Rayes Basil F.   Ibrahim Dina   Shields Anthony F.   LoRusso Patricia M.   Zalupski Mark M.   Philip Philip A.  

Investigational New Drugs, Vol. 23, Iss. 1, 2005-01 ,pp. : 57-62

Springer Publishing Company

Access to resources Recommend Favorite

Phase I dose escalation study of pegylated liposomal doxorubicin (Caelyx^®) in combination with topotecan in patients with advanced malignancies

By Ghesquières Hervé   Faivre Sandrine   Djafari Latifa   Pautier Patricia   Lhommé Catherine   Lozahic Stéphanie   Djazouli Kamel   Armand Jean-Pierre   Raymond Eric  

Investigational New Drugs, Vol. 24, Iss. 5, 2006-09 ,pp. : 413-421

Springer Publishing Company

Access to resources Recommend Favorite

Optimizing Antitumor Efficacy and Adverse Effects of Pegylated Liposomal Doxorubicin by Scheduled Plasmapheresis: Impact of Timing and Dosing

By  

Current Drug Delivery, Vol. 15, Iss. 9, 2018-11 ,pp. : 1261-1270

Bentham Science Publishers

Access to resources Recommend Favorite